GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » WACC %

CARsgen Therapeutics Holdings (HKSE:02171) WACC % :9.59% (As of Jun. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings WACC %?

As of today (2024-06-05), CARsgen Therapeutics Holdings's weighted average cost of capital is 9.59%%. CARsgen Therapeutics Holdings's ROIC % is -128.05% (calculated using TTM income statement data). CARsgen Therapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


CARsgen Therapeutics Holdings WACC % Historical Data

The historical data trend for CARsgen Therapeutics Holdings's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings WACC % Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
WACC %
- 14.43 7.46 9.73 9.71

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
WACC % Get a 7-Day Free Trial Premium Member Only 7.46 8.80 9.73 9.60 9.71

Competitive Comparison of CARsgen Therapeutics Holdings's WACC %

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings's WACC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's WACC % distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's WACC % falls into.



CARsgen Therapeutics Holdings WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, CARsgen Therapeutics Holdings's market capitalization (E) is HK$3770.467 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2023, CARsgen Therapeutics Holdings's latest one-year semi-annual average Book Value of Debt (D) is HK$116.0343 Mil.
a) weight of equity = E / (E + D) = 3770.467 / (3770.467 + 116.0343) = 0.9701
b) weight of debt = D / (E + D) = 116.0343 / (3770.467 + 116.0343) = 0.0299

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.349%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. CARsgen Therapeutics Holdings's beta is 0.90.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.349% + 0.90 * 6% = 9.749%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Dec. 2023, CARsgen Therapeutics Holdings's interest expense (positive number) was HK$5.101 Mil. Its total Book Value of Debt (D) is HK$116.0343 Mil.
Cost of Debt = 5.101 / 116.0343 = 4.3961%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0.445 / -817.477 = -0.05%, which is less than 0%. Therefore it's set to 0%.

CARsgen Therapeutics Holdings's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9701*9.749%+0.0299*4.3961%*(1 - 0%)
=9.59%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CARsgen Therapeutics Holdings  (HKSE:02171) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, CARsgen Therapeutics Holdings's weighted average cost of capital is 9.59%%. CARsgen Therapeutics Holdings's ROIC % is -128.05% (calculated using TTM income statement data). CARsgen Therapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.


Related Terms

CARsgen Therapeutics Holdings (HKSE:02171) Business Description

Traded in Other Exchanges
Address
No. 388 Yindu Road, Building 12, CMC Preparation Center, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a global clinical-stage biopharmaceutical company discovering, researching and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Guo Bingsen 2401 A concert party to an agreement to buy shares
Guo Huaqing 2101 Beneficial owner
Li Zonghai 2401 A concert party to an agreement to buy shares
Wang Huamao 2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Private Limited 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Yang Zhi 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited 2201 Interest of corporation controlled by you
Applied Biomaterial Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd. 2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd. 2101 Beneficial owner

CARsgen Therapeutics Holdings (HKSE:02171) Headlines

No Headlines